The effect of spinal manometers on cerebrospinal fluid (CSF) amyloid-β (Aβ) concentration was investigated. Pooled human CSF samples were divided in two, one half passed through a manometer into a collection tube, the other transferred directly to a collection tube. CSF was analyzed for Aβ38/40/42 using an electrochemiluminescence immunoassay. Relative to control, use of a manometer decreased Aβ38/40/42 concentration by 5.6% (±1.5SE), 4.4% (±1.7SE), and 4.3% (±2.4SE), respectively. The ratios of Aβ42 :40, Aβ42 :38, and Aβ40 :38 were not affected by manometer treatment. Factors which artificially lower CSF Aβ concentrations are relevant to clinical diagnosis for AD and study design.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
4.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
5.
BlennowK, ZetterbergH, FaganAM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb PerspectMed2, a006221.
6.
JanelidzeS, ZetterbergH, MattssonN, PalmqvistS, VandersticheleH, LindbergO, van WestenD, StomrudE, MinthonL, BlennowK, Swedish BioFINDER study group, HanssonO (2016) CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol3, 154–165.
7.
VandersticheleHMJ, JanelidzeS, DemeyerL, CoartE, StoopsE, HerbstV, MaurooK, BrixB, HanssonO (2016) Optimized standard operating procedures for the analysis of cerebrospinal fluid Aβ42 and the ratios of Aβ isoforms using low protein binding tubes. J Alzheimers Dis53, 1121–1132.
8.
StruyfsH, Van BroeckB, TimmersM, FransenE, SleegersK, Van BroeckhovenC, De DeynPP, StrefferJR, MerckenM, EngelborghsS (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis45, 813–822.
9.
SchneiderLS, MangialascheF, AndreasenN, FeldmanH, GiacobiniE, JonesR, MantuaV, MecocciP, PaniL, WinbladB, KivipeltoM (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: An appraisal from 1984 to 2014. J Intern Med275, 251–283.
RembachA, EveredLA, LiQ-X, NashT, VidaurreL, FowlerCJ, PertileKK, RumbleRL, TrounsonBO, MaherS, MooneyF, FarrowM, TaddeiK, Rainey-SmithS, LawsSM, MacaulaySL, WilsonW, DarbyDG, MartinsRN, AmesD, CollinsS, SilbertB, MastersCL, DoeckeJD (2015) Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. Alzheimers Res Ther7, 71.
12.
LuceyBP, GonzalesC, DasU, LiJ, SiemersER, SlemmonJR, BatemanRJ, HuangY, FoxGB, ClaassenJAHR, SlatsD, VerbeekMM, TongG, SoaresH, SavageMJ, KennedyM, FormanM, SjögrenM, MargolinR, ChenX, FarlowMR, DeanRA, WaringJF (2015) An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther7, 53.
13.
CicognolaC, ChiasseriniD, ParnettiL (2015) Preanalytical confounding factors in the analysis of cerebrospinal fluid biomarkers for Alzheimer’s disease: The issue of diurnal variation. Front Neurol6, 143.
14.
KaiserE, SchönknechtP, ThomannPA, HuntA, SchröderJ (2007) Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett417, 193–195.
15.
Le BastardN, AertsL, SleegersK, MartinJJ, Van BroeckhovenC, De DeynPP, EngelborghsS (2013) Longitudinal stability of cerebrospinal fluid biomarker levels: Fulfilled requirement for pharmacodynamic markers in Alzheimer’s disease. J Alzheimers Dis33, 807–822.
16.
PatersonRW, ToombsJ, ChapmanMD, NicholasJM, HeslegraveAJ, SlatteryCF, FoulkesAJM, ClarkCN, LaneCAS, WestonPSJ, LunnMP, FoxNC, ZetterbergH, SchottJM (2015) Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?Alzheimers Dement (Amst)1, 380–384.
17.
BiblM, EsselmannH, OttoM, LewczukP, CepekL, RütherE, KornhuberJ, WiltfangJ (2004) Cerebrospinal fluid amyloid β peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid β peptides. Electrophoresis25, 2912–2918.
18.
RanganathanS, PolshynaA, NichollG, Lyons-WeilerJ, BowserR (2006) Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clin Proteomics2, 91–101.
19.
SancesarioGM, EspositoZ, NuccetelliM, BernardiniS, SorgeR, MartoranaA, FedericiG, BernardiG, SancesarioG (2010) Aβ1-42 detection in CSF of Alzheimer’s disease is influenced by temperature: Indication of reversible Aβ1-42 aggregation?Exp Neurol223, 371–376.
20.
MurphyBM, SwartsS, MuellerBM, van der GeerP, ManningMC, FitchmunMI (2013) Protein instability following transport or storage on dry ice. Nat Methods10, 278–279.
21.
SlemmonJR, MeredithJ, GussV, AndreassonU, AndreasenN, ZetterbergH, BlennowK (2012) Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem120, 325–333.
22.
SlemmonJR, ShapiroA, MerckenM, StrefferJ, RomanoG, AndreasenN, ZetterbergH, BlennowK (2015) Impact of cerebrospinal fluid matrix on the detection of Alzheimer’s disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio. J Neurochem135, 1049–1058.
23.
FronekK, LangeP, SpreerA, EiffertH, NauR (2011) Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of β-amyloid and tau protein as determined by enzyme immunoassay. Dement Geriatr Cogn Disord32, 126–134.
24.
LewczukP, LelentalN, SpitzerP, MalerJM, KornhuberJ (2014) Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer’s disease: Validation of two novel assays. J Alzheimers Dis43, 183–191.
ReijnTSM, RikkertMO, Van GeelWJA, De JongD, VerbeekMM (2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid β42 and tau proteins. Clin Chem53, 859–865.
27.
FaganAM, ShawLM, XiongC, VandersticheleH, MintunMA, TrojanowskiJQ, CoartE, MorrisJC, HoltzmanDM (2011) Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol68, 1137–1144.
28.
EllisTA, LiJ, LeblondD, WaringJF (2012) The relationship between different assays for detection and quantification of amyloid beta 42 in human cerebrospinal fluid. Int J Alzheimers Dis2012, 984746.
MattssonN, ZetterbergH, BlennowK (2010) Lessons from multicenter studies on CSF biomarkers for Alzheimer’s disease. Int J Alzheimers Dis2010, pii: 610613.
Le BastardN, De DeynPP, EngelborghsS (2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem61, 734–743.
36.
del CampoM, MollenhauerB, BertolottoA, EngelborghsS, HampelH, SimonsenAH, KapakiE, KruseN, Le BastardN, LehmannS, MolinuevoJL, ParnettiL, Perret-LiaudetA, Sáez-ValeroJ, SakaE, UrbaniA, VanmechelenE, VerbeekM, VisserPJ, TeunissenC (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update. Biomark Med6, 419–430.
37.
SchoonenboomNSM, MulderC, VandersticheleH, Van ElkE-J, KokA, Van KampGJ, ScheltensP, BlankensteinMA (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: Implications for use in clinical practice. Clin Chem51, 189–195.
38.
British Standards Institution (1994) Accuracy (trueness and precision) of measurement methods and results –Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method. International Organization for Standardization, ISO 5725–1.
39.
BohmG, ZechG (2010) Introduction to statistics and data analysis for physicists. Statsref Co37, 452.
40.
SlatsD, ClaassenJA, SpiesPE, BormG, BesseKT, van AalstW, TsengJ, SjogrenMJ, Olde RikkertMG, VerbeekMM (2012) Hourly variability of cerebrospinal fluid biomarkers in Alzheimer’s disease subjects and healthy older volunteers. Neurobiol Aging33, 831e1–9.
41.
OomsS, OvereemS, BesseK, RikkertMO, VerbeekM, ClaassenJAHR (2014) Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol71, 971–977.
42.
Den DaasI, WemerJ, Abou FarhaK, TammingaW, De BoerT, SpanjersbergR, StruysMMRF, AbsalomAR (2013) Serial CSF sampling over a period of 30h via an indwelling spinal catheter in healthy volunteers: Headache, back pain, tolerability and measured acetylcholine profile. Eur J Clin Pharmacol69, 1083–1090.
43.
Terrill-UserySE, ColvinBA, DavenportRE, NicholsMR (2016) Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures. Arch Biochem Biophys597, 1–11.
44.
MuizelaarJP, MarmarouA, WardJD, KontosHA, ChoiSC, BeckerDP, GruemerH, YoungHF (1991) Adverse effects of prolonged hyperventilation in patients with severe head injury: A randomized clinical trial. J Neurosurg75, 731–739.
